Horizon Pharma has continually raised the price of Vimovo, a common painkiller combined with a drug that prevents stomach irritation, since it acquired the US rights to the medicine in November 2013 from AstraZeneca. The Dublin-based company raised the average wholesale price again earlier this month by 9.9 per cent, according to data reported by the Financial Times, taking the cost of a bottle of 60 pills to $2,979. When AstraZeneca was selling the drug in the US, the price was $138 per bottle. But since Horizon has owned the rights, it has raised the price on 11 occasions by an aggregate of more than 2,000 per cent. However, patients still end up paying more for expensive drugs such as Vimovo and Duexis in the form of higher insurance premiums.

Source: The Irish Times February 15, 2018 10:18 UTC